Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics
Pharmaceutics · 02.04.2024 · 16 (4) · 487
DOI: 10.3390/pharmaceutics16040487 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 02.04.2024. Verfasst von Leticia Rodríguez-Alcolado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hospital General de Tomelloso, 13700 Tomelloso, Spain. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Health Research Training.
Abstract (Originalsprache)
Proton-pump inhibitors (PPIs) are the most administered first-line treatment for eosinophilic esophagitis (EoE). However, only around half of EoE patients respond histologically to a double dosage of PPI. In addition, 70% of responders maintain EoE in remission after tapering the PPI dose. In order to avoid endoscopy with biopsies—the only accurate method of assessing PPI response—efforts have been made to identify PPI responder patients. The clinical or endoscopic features and biomarkers evaluated so far, however, have not proven to be sufficient in predicting PPI response. Although new approaches based on omics technologies have uncovered promising biomarkers, the specialized and complex procedures required are difficult to implement in clinical settings. Alternatively, PPI pharmacogenetics based on identifying variations in CYP2C19 and STAT6 genes have shown promising results in EoE, and could easily be performed in most laboratories. Other genetic variations have also been associated with PPI response and may explain those cases not related to CYP2C19 or STAT6. Here, we provide an overview of PPI treatment in EoE and evidence of how genetic variations in CYP2C19 and other genes could affect PPI effectiveness, and also discuss studies evaluating the role of pharmacogenetics in predicting PPI response in patients with EoE.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Hospital General de Tomelloso, 13700 Tomelloso, Spain.
- Department of Surgery, Medical and Social Sciences, Universidad de Alcalá, 28805 Alcalá de Henares, Spain.
- Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), 45071 Toledo, Spain.
- Instituto de Investigación Sanitaria La Princesa, 28006 Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain.
ORCID-Profile: Leticia Rodríguez-Alcolado, Laura Arias-González, Elena Grueso-Navarro, Alfredo J Lucendo, Emilio J Laserna-Mendieta
Förderung
- Instituto de Salud Carlos III
- Health Research Training
Zitieren
APA
Rodríguez-Alcolado, L., Navarro, P., Arias-González, L., Grueso-Navarro, E., Lucendo, A. J., & Laserna-Mendieta, E. J. (2024). Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics. Pharmaceutics, 16(4), 487. https://doi.org/10.3390/pharmaceutics16040487
Vancouver
Rodríguez-Alcolado L, Navarro P, Arias-González L, Grueso-Navarro E, Lucendo AJ, Laserna-Mendieta EJ. Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics. Pharmaceutics. 2024;16(4):487. doi:10.3390/pharmaceutics16040487
BibTeX
@article{RodrguezAlcolado2024,
author = {Rodríguez-Alcolado, Leticia and Navarro, Pilar and Arias-González, Laura and Grueso-Navarro, Elena and Lucendo, Alfredo J and Laserna-Mendieta, Emilio J},
title = {Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {4},
pages = {487},
doi = {10.3390/pharmaceutics16040487}
}
EUVIMED